Print Page  |  Close Window

Investors


Corporate Profile

Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

More »
DateTitle 
08/01/17Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 1, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2017. Recent Achievements On June 19, 2017, Rigel announced the U.S Food & Drug Administration (FDA) had accepted for filing its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persis... 
Printer Friendly Version
07/25/17Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., July 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter financial results after market close on Tuesday, August 1, 2017.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by dialing 855-892-1489 (... 
Printer Friendly Version
06/22/17Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
SOUTH SAN FRANCISCO, Calif., June 22, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP) will be presented on Saturday, June 24, 2017, from 12:30 - 12:45pm (CEST) at the European Hematology Association 22nd Annual Congress (EHA) in Madrid, Spain. Earlier this week, Rigel announced ... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.21
Change (%) - 0.06 (2.64%)
Volume744,683
Data as of 08/17/17 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $2.21 with a 52 week high of $4.38 and a 52 week low of $1.94.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.